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Studies of tumor growth and metastasis in small animal models have benefi ted greatly from the expanded availability of optical imaging techniques that specifi cally detect tumor tissue in live animals [1] and [2] . A major advantage of optical imaging is the cost-effective accessibility of the requisite instrumentation. Several promising methods use molecular approaches to enhance the specifi city of optical detection. Frequently, chosen techniques include measurement of bioluminescence, in which tumor cell lines bearing a luciferase reporter gene are detected by systemic delivery of a luminescent substrate, and gene-encoded fl uorescence of tumor cell lines expressing green or red fl uorescent proteins [3] and [4] . Although both tumor detection methods are powerful and sensitive, their major limitation is a requirement for specifi c cell lines. An alternative approach is the exploitation of high-affi nity receptor-ligand interactions to target molecular features of the tumor cell with coupled fl uorophores.
Targeting agents that have been used successfully for optical noninvasive detection of tumor xenografts in mice include monoclonal antibodies [5] and [6] , small polypeptide growth factors [7] and [8] , and peptide analogues of extracellular ligands such as endostatin [9] and somatostatin [10] . The most effective coupled fl uorophores are those with fl uorescence emission maxima in the near-infrared (NIR) range of 780 to 850 nm. Due to low-absorbance spectra of bodily fl uids and tissues, imaging in the NIR offers the advantages of relatively deep tissue penetration and low autofl uorescence [11] and [12] . Examples include targeting of the integrin α v β 3 using variations of Arg-Gly-Asp (RGD) peptides linked to Cy5.5 [13] , [14] , [15] , and [16] , Alexa Fluor 680 [13] , and IRDye 800CW [16] . Recently, epidermal growth factor (EGF) labeled with Cy5.5 was used to quantify therapeutic effi cacy of anti-EGF receptor antibodies for treating mammary carcinoma in mice [8] .
To optimize receptor-targeted signal strength in NIR optical imaging, a detailed understanding of the targeting mechanism and fl uorophore function is critical. The EGF receptor is a potential biomarker for numerous preclinical models of human cancer because its expression is elevated an order of magnitude or more relative to normal cells in cancers of the breast [17] , prostate [18] , lung [19] , ovary [20] , and brain [21] . Furthermore, its signaling functions are well characterized and accessible to convenient high-throughput in vitro validation assays to ensure that bioactivity of the ligand is maintained despite chemical coupling. For example, EGF binds to a cell surface transmembrane receptor tyrosine kinase, and this induces dimerization of the receptors, triggering a phosphorylation cascade through numerous extracellular-regulated kinases [22] . Because antibodies are available to specifi cally quantify the phosphorylated form of several kinases, activity of EGF may be verifi ed directly by receptor binding and indirectly by stimulated kinase activity.
We previously conjugated IRDye 800CW to EGF to track longitudinal growth of orthotopic prostate tumors in mice [23] and found that the conjugate was a sensitive tumor targeting agent with excellent tissue penetration. We hypothesized that an aspect of the normal function of EGF contributing to the strong signal obtained from this agent could be receptor-mediated endocytosis of the ligand-receptor complex. This would imply that initial high-affi nity binding of the targeting agent is essential for maximal fl uorescence signal strength in animals. Thus, animal numbers could be minimized in imaging experiments if suboptimal conjugate binding in vitro was found to correlate with reduced tumor targeting effi cacy in vivo. Furthermore, it would be very powerful to have a straightforward in vitro assay that could directly predict relative effi ciencies of two different drugs or ligands with the same in vivo target. In this study, we used IRDye 800CW EGF to target A431 human epidermoid carcinoma cells in vitro and in vivo. Specifi cally, we compared whole cell binding, extracellular signal-regulated kinase (ERK) phosphorylation, and subcutaneous tumor targeting of optimal and damaged conjugates. Our characterization confi rms that poor quality of a receptor targeting agent can be detected by measuring in vitro binding equilibria and that reduced bioactivity is detrimental to imaging sensitivity. 
Materials and methods

Cell
Characterization of IRDye 800CW EGF binding specifi city in vitro
The binding specifi city of the IRDye 800CW EGF compound was evaluated on A431 and PC3M-LN4 cells by an In-Cell Western assay [23] and [24] . Briefl y, cells were grown to approximately 90% confl uency in a microtiter plate (Nunc, Roberts, WI, USA) and starved for 2 h in serum-free media. For binding assays, starvation media were replaced with media containing increasing concentrations of IRDye 800CW only (0.002-3.3 μM) or IRDye 800CW EGF (0.01-70 nM). Specifi city of the labeled compound was evaluated by competition assays in which starvation media were replaced with media containing unlabeled EGF (in increasing concentrations from 0.01 to 2.14 μM) + IRDye 800CW EGF (70 nM) or C225 (0.5-200 μg/ml) + IRDye 800CW EGF (70 nM). Cells were incubated at room temperature (25 °C) for 2 min and fi xed with 4% formaldehyde solution for 20 min. Four washes in 1 × phosphate-buffered saline (PBS) + 0.1% Triton X-100 were done to remove unbound dye and permeabilize the cells. The plates were blocked in Odyssey Blocking Buffer for 1.5 h and then incubated with TO-PRO-3 (1:5000) for normalization of cell number using the 700-nm channel. Washing steps were repeated, and the plate was scanned on Aerius. Quantifi cations were normalized by ratiometric analysis of the 700-nm values applied to the 800-nm values.
Preparation of targeting agents
High-quality targeting agents were prepared by standard fast protein liquid chromatography (FPLC) methods. All separations were performed on an Agilent 1100 series HPLC system (Agilent Technologies, Santa Clara, CA, USA). Sample detection employed a diode array detector set at 260 and 780 nm, and purifi cations were carried out at 5 °C. Standard FPLC conditions were achieved with this instrument using an isocratic method suitable for size exclusion chromatography. Following conjugation, the coupling mixture was applied to a 35 × 250-mm Omnifi t column (Western Analytical Products, Wildomar, CA, USA) packed with Superdex 30 gel fi ltration media (GE Healthcare/Amersham Biosciences, Piscataway, NJ, USA). This column was equilibrated and eluted at 0.5 ml/min (6 bar pressure) with isocratic 1 × PBS (pH 7.4). The eluted material was fi lter sterilized by passage through a 0.2-μm syringe fi lter into a sterile container. Absorbance at 280 nm was used to calculate EGF concentration from the published molar extinction coeffi cient. Dual wavelength absorbances were used to determine the dye/protein ratio, which was maintained consistently across all coupling reactions. Dual wavelength absorbance traces from size exclusion chromatography were also used to determine the relative amounts of coupled and unreacted dye in all preparations.
Poor-quality targeting agents were prepared by subjecting unlabeled EGF or IRDye 800CW EGF to HPLC purifi cation, which is detrimental to protein activity because of the harsh denaturing solvent conditions [25] . A reversephase C18 Zorbax column (250 × 9.6 mm, 300 Å pore size, 5 μm particle size) was used. Solvents included aqueous 50 mM triethylammonium acetate (TEAA, pH 5.9) (A) and acetonitrile (B) in a gradient of 20% B to 31% B in 15 min. The purifi cation was performed at a fl ow rate of 4.7 ml/ min (100 bar pressure). Sample was protected from light, dried overnight under vacuum, reconstituted in 1 × PBS, and applied to a cation (Na + resin) exchange column equilibrated with 1 × PBS. Following elution from the column with 1 × PBS, the sample was lyophilized. Protein concentration, dye/protein ratio, and unreacted dye quantity were measured as above.
Quantifi cation of downstream signaling by IRDye 800CW EGF
The ability of the targeting agent to stimulate ERK phosphorylation in A431 cells was compared with that of unlabeled EGF. Cells at 90% confl uence in a 96-well plate were serum starved for 2 h. Starvation media were replaced with stimulation media containing 0.03 to 14 nM IRDye 800CW EGF (FPLC), IRDye 800CW EGF (HPLC), unlabeled EGF (FPLC), or unlabeled EGF (HPLC). Cells were incubated for 2 min at room temperature followed by fi xation and permeabilization as above. An initial scan on Aerius was done to obtain the level of signal from the conjugated EGF bound to receptors. Then plates were blocked for 1.5 h in Odyssey Blocking Buffer followed by incubation with anti-β-tubulin (1:100) and anti-p-ERK (1:100) for 1.5 h at room temperature. Plates were washed four times in 1 × PBS + 0.1% Tween 20 prior to incubation with IRDye 800CW goat antirabbit (1:800) and IRDye 680 goat anti-mouse (1:200) antibody conjugates for 1 h. Cells were washed again, and the plate was scanned on the Aerius. The fi nal ratiometric analysis was adjusted for the initial binding signal, and p-ERK signal was normalized to β-tubulin.
Subcutaneous injections
Male NOD/SCID mice (Jackson Laboratory, Bar Harbor, ME, USA) and athymic Nu/Nu mice (Charles River, Wilmington, MA, USA) used in these experiments were maintained under the supervision and guidelines of the University of Nebraska-Lincoln Institutional Animal Care and Use Committee. PC3M-LN4 cells were trypsinized, washed, and resuspended at 5 × 10 6 cells/ml in serum-free MEM [26] . Each NOD/SCID mouse was injected subcutaneously in the fl ank with 100 μl of cell suspension (0.5 × 10 6 cells) using a 1-ml insulin syringe. Tumors reached approximately 0.5 cm in size at 4 weeks. A431 cells were trypsinized, washed, and resuspended at 2 × 10 7 cells/ml in serum-free medium for subcutaneous injections in the fl ank (2 × 10 6 cells) of male athymic Nu/Nu mice. Animals were carried for approximately 2 weeks until tumors reached roughly 0.5 cm in size.
In vivo imaging of IRDye 800CW EGF
NIR fl uorescence imaging in live animals was performed with a research prototype LI-COR Biosciences small animal imager. The LI-COR instrument is a light tight chamber equipped with a cooled charge-coupled device (CCD) camera, area illumination via diode lasers, and a selection of excitation and detection optical fl uorescent fi lters tuned specifically for IRDye 800CW. Images were acquired and analyzed with Wasabi software (Hamamatsu Photonics, Hamamatsu City, Japan) or Adobe Photoshop (Adobe Systems, San Jose, CA, USA). NOD/SCID mice were shaved prior to image collection. All mice were anesthetized with 2% isofl urane throughout procedures.
To establish initial conditions, IRDye 800CW EGF (1 nmol) was injected via the tail vein into a tumor-negative mouse of each strain and evaluated for systemic clearance by NIR imaging at intervals of 1 to 24 h over a period of 3 days, after which time more than 90% of the signal had cleared. Then mice bearing subcutaneous PC3M-LN4 or A431 tumors (diameter ~0.5 cm) were injected with IRDye 800CW EGF (1 nmol) and evaluated for tumor-specifi c retention of the agent by NIR imaging at 24-h intervals for up to 8 days.
Signal-to-noise ratios (SNRs) calculated as described below were used to determine an optimal time point of 72 to 96 h for imaging tumors. Subsequently, an additional eight athymic mice with A431 tumors were injected to compare signal strength of the targeting agents prepared by different methods. One mouse was injected with 0.9% saline, one mouse received unconjugated IRDye 800CW, two mice were given IRDye 800CW EGF (1 nmol) from sources A and B purifi ed by FPLC, and four mice were injected with HPLC-damaged IRDye 800CW EGF (1 nmol) purifi ed by HPLC. Animals were imaged 3 days postinjection and euthanized. Tumors were excised, weighed, measured, and paraffi n embedded for section scan analysis on Odyssey.
Statistical analysis
Images for each mouse were normalized using the same intensity scale with a common minimum and maximum value. SNR was calculated using the following formula:
Regions of interest (ROIs) with identical areas were used for both tumor and background. ROIs were quantifi ed for total pixel and mean pixel values. The standard deviation of mean backgrounds was calculated using three to fi ve ROIs. This calculation yields the number of standard deviations over background represented by the suspect tumor/signal. Due to tumor size differences between the animals receiving quality targeting agents, tumor signal minus background signal of similar-size ROI was then corrected for area (pixels). The percentage difference from FPLC-purifi ed agent was determined for HPLC-purifi ed agents.
Tissue section analysis
After fi nal imaging (day 3 or 4 postinjection), animals were sacrifi ced. Tumors were excised, scanned on Odyssey, weighed, measured, and preserved in Z-fi x (Anatech, Battle Creek, MI, USA), followed by paraffi n embedding and tissue sectioning. Sections (5 μm thickness) were scanned in both the 700-nm channel, for tissue autofl uorescence, and the 800-nm channel, for the targeted IRDye 800CW EGF fl uorescence signal using Odyssey. The area-weighted fl uorescence signal from the 800-nm channel was used to compare targeting agent specifi cities among experimental conditions.
Results and discussion
In vitro specifi city of IRDye 800CW EGF for tumor cell lines
Effective use of whole animal NIR optical imaging for sensitive detection of tumor tissue requires highly specifi c biomarkers that can be labeled to illuminate tumor cells within live mice. Maximal emission of IRDye 800CW is 789 nm, so it falls in an optimal region of the spectrum to obtain superior signal strength. We previously coupled EGF to IRDye 800CW and found this targeting agent to be highly sensitive and specifi c due to its strong signal [23] . Our goal in the current study was to determine an aspect of EGF biological function quantifi able in vitro that refl ects maximal tumor targeting potential.
We fi rst characterized binding of the targeting agent to A431 cells by a microplate NIR fl uorescence assay as we had done previously for PC3M-LN4 human prostate tumor cells [23] . Confl uent monolayer cultures of A431 cells were established in 96-well plates and treated with increasing concentrations of IRDye 800CW EGF to establish a doseresponse curve for binding of the targeting agent to EGF receptors on the cells. Fluorescence signal became signifi cant at 1 nM concentrations and increased exponentially in a concentration-dependent fashion ( Figure 1A ). To verify receptor targeting, we performed the same measurements with unconjugated dye, showing negligible increases in fl uorescence over a similar concentration course ( Figure 1A , circles). The specifi city of the conjugate for the EGF receptor on the cells was evaluated by competitions with unlabeled EGF ( Figure 1B ) and with C225, a monoclonal antibody that blocks ligand binding by the EGF receptor [27] (Figure 1C To confi rm that bioactivity of the targeting agent was indicated accurately by binding affi nity, we used an In-Cell Western assay that was developed previously for the quantifi cation of kinase phosphorylation in whole cells [24] . No signifi cant decrease in ERK phosphorylation was noted between cells treated with equimolar concentrations of unlabeled EGF and IRDye 800CW EGF (data not shown). This is consistent with results from other investigators who have shown that both fl uorescein isothiocyanate (FITC)-EGF [7] and fl uorescent quantum dot-EGF [28] conjugates are effectively internalized by ligand-induced endocytosis of the bound EGF receptor complex, also a downstream effect of biologically intact EGF.
Impairment of binding of EGF and EGF-stimulated ERK phosphorylation by HPLC purifi cation
We next evaluated whether the microplate binding and In-Cell Western assays could effectively distinguish between ligands with differential binding affi nities. To obtain low-affi nity ligands for comparisons, we conjugated IRDye 800CW to EGF from four independent commercial sources and subjected each conjugate to HPLC purifi cation. Binding of these four targeting agents (denoted A, B, C, and D in Figure 2 ) to A431 cells was compared by NIR fl uorescence intensity to the binding of standard maximally active FPLC-purifi ed conjugate from sources A and B. All four preparations demonstrated signifi cant reductions in binding (up to 60%) at all concentrations (Figure 2A) . Thus, the damage infl icted on EGF by HPLC treatment dramatically affected its cell binding potential. When we assayed p-ERK levels using the four targeting agents compared with unlabeled (data not shown) or conjugated EGF from sources A and B (Figure 2B ), the best performance of any HPLC-purifi ed compound was 28% of unlabeled EGF stimulation. Reduced levels of ERK phosphorylation confi rmed compromised function of the HPLCtreated targeting agents.
Kinetics of IRDye 800CW EGF clearance in vivo
Ultimately, our goal was to determine whether impaired function of the EGF receptor targeting agent in vitro would correlate with poor tumor targeting in mice. We fi rst determined clearance kinetics of the targeting agent in normal and tumor-bearing mice. Clearance was monitored by injecting animals with 1 nmol of FPLC-purifi ed IRDye 800CW EGF via the tail vein and collecting NIR images over time from 15 min to 24 h ( Figure 3A) . The pseudo-colored images depict the color-enhanced fl uorescence intensity superimposed on white light images of a representative mouse. Fluorescence intensity in regions of interest encompassing the whole animal (large ROI) or limited to the abdominal area (small ROI) was quantifi ed to evaluate clearance. We Figure 1 . In vitro binding specifi city of IRDye 800CW EGF for tumor cells in culture. A431 cells cultured to 90% confl uence in 96-well plates were incubated with increasing concentrations of IRDye 800CW EGF (diamonds) or unconjugated nonreactive IRDye 800CW (circles) for 2 min and then washed, fi xed, permeabilized, and stained with TO-PRO-3 (A). For competitions, cells were incubated with a fi xed concentration of IRDye 800CW EGF (70 nM) containing the indicated concentrations of unlabeled EGF (B) or C225, an EGF receptor blocking antibody (C). All plates were scanned at two wavelengths on the Aerius near-infrared scanner. The 800-nm signal, normalized to the 700-nm control, is plotted as the means ± SD of three replicate wells.
Figure 2.
Biological activity elicited by labeled EGF. EGF from four sources (denoted as A, B, C, and D) was conjugated to IRDye 800CW and purifi ed by HPLC. A431 cells at 90% confl uence in 96-well plates were stimulated with the indicated concentrations of the respective agents or with the maximally active FPLC-purifi ed conjugates corresponding to sources A and B. The plate was scanned to quantify binding of the IRDye 800CW EGF targeting agents (A). The extent of ERK phosphorylation stimulated in each condition was assessed in the same plate by the In-Cell Western assay using antibodies to total ERK and p-ERK (B). The mean ± SD for three replicate wells is plotted.
observed an initial increase in whole animal fl uorescence intensity for the fi rst 3 to 4 h as the targeting agent circulated to the capillaries of the skin. Subsequently, the signal was seen to pass through the liver, intestines, kidneys, and bladder. The analysis confi rmed that 75% of the signal cleared after 8 h and that more than 90% cleared after 24 h.
Then we monitored a similar time course for clearance of the targeting agent from tumor-positive animals ( Figure 3B ). Mice bearing subcutaneous tumors of approximately 0.5 cm in diameter (measured by digital calipers) were injected as above with IRDye 800CW EGF, imaged immediately, and imaged repeatedly at 24-h intervals. As observed for the tumor-negative controls, whole animal and abdominal signal intensity peaked at 3 to 4 h but had diminished by more than 90% within 24 h (data not shown). Analysis of SNR comparing mean fl uorescence intensity in an arbitrarily chosen ROI within the tumor, designated as a blue ellipse, to the mean of four background areas of identical size, shown as orange ellipses, exhibited an initial time-dependent increase. Eventual saturation of SNR indicated that the time of maximal sensitivity for imaging was 72 to 96 h, and subsequent images were collected at 72 h ( Figure 3B ). In vivo, IRDye 800CW EGF fl uorescence following systemic clearance was amplifi ed in the tumors relative to the whole animals and was also specifi c, Signal intensities (at 789 nm) were normalized to background fl uorescence and plotted using the whole animal (large ROI, dark bars) or an arbitrary abdominal ellipse (small ROI, light bars) as ROIs. (B) IRDye 800CW EGF was injected intravenously into mice with subcutaneous PC3M-LN4 prostate tumor xenografts, and images were collected at the indicated times postinjection. SNR was calculated using a single elliptical ROI denoted on the tumor in blue and four background ellipses (orange) placed arbitrarily in irrelevant adjacent sites on the fl ank as shown. Fluorescence is also present in the kidneys in these dorsal views. Calculated SNR was plotted to obtain an optimal imaging time point for subsequent experiments.
as shown by antibody blocking. The sensitivity of this fl uorescence signal lends support to the choice of EGF receptor as an epithelial or prostate tumor target and demonstrates that IRDye 800CW is an effective labeling fl uorophore.
Subcutaneous tumor targeting by IRDye 800CW EGF
To optimize targeting and tumor-specifi c signal accumulation in noninvasive imaging, it is important to understand the functional parameters of the biomarker and its response to the target. Using the In-Cell Western assay, we detected impaired binding and response of the EGF receptor signaling cascade when the EGF conjugate was subjected to HPLC treatment. We performed an animal imaging study to determine whether impaired binding function would translate to poor tumor signal. FPLC-or HPLC-purifi ed IRDye 800CW EGF from two sources (A and B) was injected via the tail vein into athymic mice bearing approximately 0.5-cm subcutaneous A431 tumors. Mice were imaged 3 days postinjection (Figure 4 ). The arrowheads in Figure 4 indicate positions of detected tumor tissue in these representative fl uorescence images, which have been corrected for background. Figs. 4A and C illustrate signal intensity in animals injected with the FPLC-purifi ed targeting agent, and Figs. 4B and D show the effect of the corresponding HPLC form. These images were analyzed to determine total fl uorescence in the tumor (Table 1) . Mice receiving HPLC-purifi ed targeting agents from the two different preparations had approximately 28 and 64% lower signal compared with mice injected with minimally damaged agents ( Table 1) . Similar results were obtained when damaged agents were injected in mice bearing 22Rv1 prostate tumors, confi rming that this phenomenon is not unique to the A431 cells. In images not shown, additional mice were injected with HPLC-purifi ed probes from sources C and D, but the fl uorescence signal from these animals was diminished 80 to 90% with respect to that calculated for the animals receiving optimized preparations (Table 1) . Thus, the magnitude of the differences varied considerably, but a targeting agent exhibiting suboptimal signaling potential in vitro correlated strongly with poor signal strength in live animal imaging.
Finally, tumors were excised and sectioned for fl uorescence scanning analysis to verify whether signal intensity measured in the animal was attributable to fl uorescence in the tumor tissue and whether the intensity was consistent throughout the tumor. Sections were scanned on the Odyssey in two channels, and the corresponding merged images are shown as insets in Figure 4 . Red represents tissue autofl uorescence in the 700-nm channel, and green denotes specifi c fl uorescence in the 800-nm channel resulting from IRDye 800CW EGF. Normalized fl uorescence of the tissue sections is presented in Table 1 . Signal intensity was evident throughout the tumors irrespective of targeting agent. Consistent with results from intact animal image analysis, sections exhibited signal reductions of approximately 25 to 60%. Thus, performance of targeting agents damaged by HPLC purifi cation, as identifi ed in vitro by the assay for ERK phosphorylation, again translated to poor outcomes in whole animal imaging experiments.
In conclusion, we have characterized an effective targeting agent for noninvasive optical detection and tracking of tumors in mice. The fl uorophore used, IRDye 800CW, can be easily coupled to many ligand or targeting molecules of interest. We have found that an in vitro assay that detects binding and effi cacy of EGF-conjugated products in stimulating downstream biological function is an accurate estimate of targeting effi cacy in vivo. We expect this application to have further value in probe and drug development as a correlate assay for other biolabels to estimate competitive ligand and/or drug interactions in vivo. Figure 3 , and for panels C and D source B was used. Images were collected on anesthetized animals at 72 h postinjection. Tumors were excised, fi xed, paraffi n embedded, and sectioned for fl uorescence signal determination by twocolor scanning on the Odyssey (inset panels). 
